医学
气道
哮喘
免疫学
重症监护医学
过敏
生物制剂
炎症反应
治疗方法
鼻窦炎
炎症
慢性鼻-鼻窦炎
临床实习
气道阻塞
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-11-17
卷期号:106 (42): 4583-4604
标识
DOI:10.3760/cma.j.cn112137-20260429-01162
摘要
To standardize the clinical application of biologic targeted therapy for airway inflammatory diseases in China, Chinese Society of Allergy and Asthma Group of Chinese Thoracic Society, Chinese Medical Association, with multidisciplinary experts, developed the"Expert consensus on targeted biologic therapy for airway inflammatory diseases (2026 edition)"using an evidence-based approach, which formulated 15 recommendations. The consensus systematically elaborated on the classification, characteristics, and core inflammatory mechanisms of airway inflammatory diseases; described the mechanisms of action, clinical efficacy, and safety profiles of biologics for asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis and allergic rhinitis, and highlighted upper and lower airway comorbidities and their shared inflammatory pathways, thereby providing a reference for the precise and safe use of biologics in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI